← Back to Clinical Trials
Recruiting NCT07244445

NCT07244445 Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07244445
Status Recruiting
Phase
Sponsor Ian J. Neeland, MD
Condition Dietary Change
Study Type INTERVENTIONAL
Enrollment 108 participants
Start Date 2026-01-29
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
PistachiosDual-energy X-ray absorptiometry (DEXA) scans

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 108 participants in total. It began in 2026-01-29 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study will look at how eating pistachios every day might affect participants weight, how healthy their diet is, and how they feel when eating. Investigators want to see if adding pistachios to meals for 12 weeks helps participants feel fuller, have more energy, and improve body composition. The study will include adults who have been taking GLP-1 medicines like semaglutide or tirzepatide for at least three months. Investigators also want to see if eating pistachios improves overall diet quality and health markers like tiredness and certain levels in blood.

Eligibility Criteria

Inclusion Criteria: * Individuals with a BMI ≥30 kg/m2 or with a BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been continuously using semaglutide or tirzepatide for three months for a clinical indication and remain on the therapy at the time of enrollment Exclusion Criteria: * No use or contraindication to use of a GLP-1 RA * Known allergy to nuts * Pregnant or breastfeeding * Incarcerated

Contact & Investigator

Central Contact

Ian Neeland, MD

✉ Ian.Neeland@UHhospitals.org

📞 216-844-5965

Principal Investigator

Ian Neeland, MD

PRINCIPAL INVESTIGATOR

University Hospitals Cleveland Medical Center

Frequently Asked Questions

Who can join the NCT07244445 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Dietary Change. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07244445 currently recruiting?

Yes, NCT07244445 is actively recruiting participants. Contact the research team at Ian.Neeland@UHhospitals.org for enrollment information.

Where is the NCT07244445 trial being conducted?

This trial is being conducted at Clevland, United States.

Who is sponsoring the NCT07244445 clinical trial?

NCT07244445 is sponsored by Ian J. Neeland, MD. The principal investigator is Ian Neeland, MD at University Hospitals Cleveland Medical Center. The trial plans to enroll 108 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology